37 results on '"Panteghini, Mauro"'
Search Results
2. Biological variation of two serum markers for preeclampsia prediction.
- Author
-
Braga F, Ferraro S, Borille S, and Panteghini M
- Subjects
- Adult, Female, Humans, Limit of Detection, Luminescent Measurements, Middle Aged, Placenta Growth Factor standards, Pre-Eclampsia blood, Pregnancy, Vascular Endothelial Growth Factor Receptor-1 blood, Vascular Endothelial Growth Factor Receptor-1 standards, Young Adult, Biomarkers blood, Immunoassay methods, Placenta Growth Factor blood, Pre-Eclampsia diagnosis
- Published
- 2020
- Full Text
- View/download PDF
3. Daily monitoring of a control material with a concentration near the limit of detection improves the measurement accuracy of highly sensitive troponin assays.
- Author
-
Aloisio E, Pasqualetti S, Dolci A, and Panteghini M
- Subjects
- Biomarkers blood, Humans, Limit of Detection, Luminescent Measurements, Myocardial Infarction diagnosis, Quality Control, Reagent Kits, Diagnostic, Troponin I standards, Immunoassay methods, Troponin I blood
- Published
- 2020
- Full Text
- View/download PDF
4. Serum α-fetoprotein in pediatric oncology: not a children's tale.
- Author
-
Ferraro S, Panzeri A, Braga F, and Panteghini M
- Subjects
- Age Factors, Carcinoma, Hepatocellular diagnosis, Hepatoblastoma diagnosis, Humans, Immunoassay standards, Liver Neoplasms diagnosis, Neoplasms, Germ Cell and Embryonal diagnosis, Reference Values, Sex Factors, Testicular Neoplasms diagnosis, alpha-Fetoproteins standards, Immunoassay methods, alpha-Fetoproteins analysis
- Abstract
Background Measurement of α-fetoprotein (AFP) concentrations in the serum of infants is useful for the management of testicular germ cell tumors, hepatoblastoma and hepatocellular carcinoma. Here, we provide a critical review of the available information about pediatric reference intervals (RI), focusing on their utility in interpreting AFP as an aid for cancer diagnosis. Content Evidence sources in the available literature were critically appraised. Out of 3873 retrieved papers, 24 were finally selected and carefully inspected, and six of them overcame exclusion criteria (i.e. methodological limitations in the study design, statistical gaps, drawbacks in traceability of the AFP assay to higher order materials and/or biased reporting of AFP results). Preterm and term infants up to the 3rd month of life exhibited the highest average AFP concentrations, but the attempt of defining RI by data pooling and partitioning for age intervals was impeded by the wide variability of data. The inability of defining robust RI in the first months of life made difficult, if not impossible, using upper reference limits for ruling out malignancies with a single AFP result. Evaluating the behavior of AFP concentrations 5 days from the baseline result, if this exceeds risk thresholds partitioned for age, according to the formula Xt=X0*2-t/HL (where: t=days elapsed for AFP retest; HL=AFP half-life according to age; X0=AFP baseline concentration, and Xt=predicted AFP concentration at day 5), could give a better information. Summary Novel studies defining AFP RI in infants based on robust methodology are warranted to improve the interpretation of AFP results in pediatric oncology. In the meantime, algorithms based on both serum AFP absolute concentrations and HL may aid in cancer diagnosis.
- Published
- 2019
- Full Text
- View/download PDF
5. Reference intervals for the Kryptor second-generation chromogranin A assay.
- Author
-
Ferraro S, Borille S, and Panteghini M
- Subjects
- Antibodies, Monoclonal immunology, Automation, Chromogranin A immunology, Humans, Protein Folding, Reference Values, Chromogranin A analysis, Immunoassay standards
- Published
- 2016
- Full Text
- View/download PDF
6. Verification of the harmonization of human epididymis protein 4 assays.
- Author
-
Ferraro S, Borille S, Carnevale A, Frusciante E, Bassani N, and Panteghini M
- Subjects
- Female, Humans, Biological Assay methods, Electrochemical Techniques methods, Immunoassay methods, Luminescent Measurements methods, Ovarian Neoplasms diagnosis
- Abstract
Background: Serum human epididymis protein 4 (HE4) has gained relevance as an ovarian cancer (OC) biomarker and new automated methods have replaced the first released manual EIA by tracing results to it. We verified agreement and bias of automated methods vs. EIA as well as possible effects on patients' management., Methods: One hundred and fifteen serum samples were measured by Abbott Architect i2000, Fujirebio Lumipulse G1200, Roche Modular E170, and Fujirebio EIA. Passing-Bablok regression was used to compare automated assays to EIA and agreement between methods was estimated by Lin's concordance correlation coefficient (CCC). The bias vs. EIA was estimated and compared to specifications derived from HE4 biological variation., Results: Median (25th-75th percentiles) HE4 concentrations (pmol/L) were 84.5 (60.1-148.8) for EIA, 82.7 (50.3-153.9) for Abbott, 89.1 (55.2-154.9) for Roche, and 112.2 (67.8-194.2) for Fujirebio. Estimated regressions and agreements (95% confidence interval) were: Abbott=1.01(0.98-1.03) EIA-4.8(-7.5/-2.6), CCC=0.99(0.99-1.00); Roche=0.91(0.89-0.93) EIA+5.7(4.2/8.0), CCC=0.98(0.98-0.99); Fujirebio=1.20(1.17-1.24) EIA+ 2.4(-0.6/4.9), CCC=0.97(0.96-0.98). The average bias vs. EIA resulted within the desirable goal for Abbott [-3.3% (-6.1/-0.5)] and Roche [-0.2% (-3.0/2.5)]. However, while for Abbott the bias was constant and acceptable along the measurement concentration range, Roche bias increased up to -28% for HE4 values >250 pmol/L. Lumipulse showed a markedly positive bias [25.3% (21.8/28.8)]., Conclusions: Abbott and Roche assays exhibited a good comparability in the range of HE4 values around the previously recommended 140 pmol/L cut-off. For patient monitoring, however, the assay used for determining serial HE4 must not be changed as results from different systems in lower and higher concentration ranges can markedly differ.
- Published
- 2016
- Full Text
- View/download PDF
7. Avoid capture of interfering molecules in cardiac troponin immunoassays: working in shifts.
- Author
-
Panteghini M
- Subjects
- Humans, Limit of Detection, Troponin I blood, Immunoassay methods, Myocardium metabolism, Troponin I metabolism
- Published
- 2013
- Full Text
- View/download PDF
8. Commutability of the ERM-DA470k reference material for two assays measuring serum albumin using immunochemical principles.
- Author
-
Infusino I, Braga F, Valente C, and Panteghini M
- Subjects
- Humans, Immunoassay standards, Nephelometry and Turbidimetry standards, Reference Standards, Serum Albumin immunology, Serum Albumin standards, Immunoassay methods, Nephelometry and Turbidimetry methods, Serum Albumin analysis
- Published
- 2011
- Full Text
- View/download PDF
9. Revaluation of biological variation of glycated hemoglobin (HbA(1c)) using an accurately designed protocol and an assay traceable to the IFCC reference system.
- Author
-
Braga F, Dolci A, Montagnana M, Pagani F, Paleari R, Guidi GC, Mosca A, and Panteghini M
- Subjects
- Adult, Biomarkers analysis, Edetic Acid, Female, Humans, Male, Middle Aged, Reference Standards, Reference Values, Glycated Hemoglobin analysis, Immunoassay standards
- Abstract
Background: Glycated hemoglobin (HbA(1c)) has a key role for diagnosing diabetes and monitoring glycemic state. As recently reviewed, available data on HbA(1c) biological variation show marked heterogeneity. Here we experimentally revaluated these data using a well designed protocol., Methods: We took five EDTA whole blood specimens from 18 apparently healthy subjects on the same day, every two weeks for two months. Samples were stored at -80°C until analysis and assayed in duplicate in a single run by Roche Tina-quant® Gen.2 immunoassay. Data were analyzed by the ANOVA. To assess the assay traceability to the IFCC reference method, we preliminarily carried out a correlation experiment., Results: The bias (mean±SD) of the Roche immunoassay was 0.3%±0.7%, confirming the traceability of the employed assay. No difference was found in HbA(1c) values between men and women. Within- and between-subject CV were 2.5% and 7.1%, respectively. Derived desirable analytical goals for imprecision, bias, and total error resulted 1.3%, 1.9%, and 3.9%, respectively. HbA(1c) had marked individuality, limiting the use of population-based reference limits for test interpretation. The estimated critical difference was ~10%., Conclusions: For the first time we defined biological variation and derived indices for the clinical application of HbA(1c) measurements using an accurately designed protocol and an assay standardized according to the IFCC., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
10. Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material.
- Author
-
Infusino I, Valente C, Dolci A, and Panteghini M
- Subjects
- Calibration, Humans, Reference Standards, Ceruloplasmin analysis, Ceruloplasmin standards, Immunoassay methods, Immunoassay standards, Serum chemistry
- Abstract
The purpose of measurement standardization is to achieve closer comparability of results obtained using different commercial systems. Regarding serum protein immunoassays, a reference preparation (BCR-470) was released in 1993 and adopted by manufacturers across the world to value-assign their assay calibrators for routine methods to reduce method-dependent variation. Moving from nephelometric (Beckman Immage 800) to turbidimetric determination (Roche Cobas c 501) of seven serum proteins, we preliminarily checked the comparability of results between the two systems. The study was performed according to the CLSI EP9-A protocol on 30 fresh sera, tested on each system in duplicate, and subdivided on two different days, without recalibration and using manufacturers' control materials to validate the runs. Both manufacturers' package inserts provide statements that kit calibrators are traceable to BCR-470. Suggested reference intervals are also the same. Although a fairly good correlation was observed (r = 0.955), the comparison of ceruloplasmin methods produced evidence of highly significant proportional (regression slope, 0.572) and constant bias (intercept, 0.05 g/L). Absolute and percentage mean differences were -0.11 g/L (95% confidence interval (CI) -0.13 to -0.10 g/L) and -39.1% (CI -43.1 to -35.2%), respectively. No other evaluated proteins showed similar problems. Lacking a ceruloplasmin reference method, it is impossible to demonstrate that one of the two assays produces true ceruloplasmin values. The problem is, however, that results coming from the two assays are clearly not comparable. This may be either due to a lack of commutability of the reference material with biological samples in the evaluated assays or to calibration problems by manufacturers in one of the stages of the calibration hierarchy.
- Published
- 2010
- Full Text
- View/download PDF
11. Assay-related issues in the measurement of cardiac troponins.
- Author
-
Panteghini M
- Subjects
- Antibodies blood, Biomarkers blood, Humans, Myocardial Infarction blood, Sensitivity and Specificity, Immunoassay, Myocardial Infarction diagnosis, Troponin I blood
- Abstract
The recently released document by the Global Task Force on the universal definition of myocardial infarction (MI) has strengthened the role of cardiac troponin increase as the main criterion for MI diagnosis. Despite this pivotal role in clinical decisions, a number of assay-related issues can still markedly affect the test performance in the everyday practice. Regarding imprecision and analytical sensitivity, the performance of commercial assays is variable. Moreover, at least for troponin I, there is a lack of standardization among assay results. Appropriate cut points (99th percentile limit of the reference value distribution and/or 10% CV concentration value) can be established only if the assay performance is known and taken into account. Key characteristics to be defined include characterization by appropriate experimental and statistical protocols of the assay detection limit, total imprecision, and definition of the 99th percentile limit of the reference population. The widespread introduction of cardiac troponin measurements is an undoubted improvement, but some performance differences still exist with commercial assays, which most clinicians are unaware of and may give rise to wrong marker interpretation.
- Published
- 2009
- Full Text
- View/download PDF
12. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure.
- Author
-
Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, and Mair J
- Subjects
- Antibody Specificity, Biomarkers blood, Calibration standards, Cross Reactions, False Positive Reactions, Female, Heart Failure diagnosis, Humans, Male, Natriuretic Peptide, Brain immunology, Patient Selection, Peptide Fragments immunology, Reference Standards, Reproducibility of Results, Research Design standards, Heart Failure blood, Immunoassay standards, Natriuretic Peptide, Brain blood, Peptide Fragments blood
- Published
- 2007
- Full Text
- View/download PDF
13. Quality specifications for B-type natriuretic peptide assays.
- Author
-
Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, Pagani F, Christenson RH, and Jaffe AS
- Subjects
- Biomarkers blood, Calibration, Humans, Practice Guidelines as Topic, Quality Control, Sensitivity and Specificity, Immunoassay standards, Natriuretic Peptide, Brain blood, Nerve Tissue Proteins blood, Peptide Fragments blood, Protein Precursors blood
- Abstract
Background: The objective of this report is to improve the quality of immunochemical measurements of B-type natriuretic peptide (BNP) and its N-terminal propeptide (NT-proBNP). The recommendations proposed are intended for use by manufacturers of commercial assays, by clinical laboratories using those assays, by clinical trial groups and research investigators, and by regulatory agencies, such as the United States Food and Drug Administration., Methods: A group of cardiac biomarker experts reviewed and abstracted the scientific literature to provide recommendations pertaining to the quality specifications for BNP/NT-proBNP assays., Results: The evidence-based recommendations encourage manufacturers to endorse and consistently follow the proposed recommendations; encourage that all package inserts for BNP/NT-proBNP immunoassays include uniform information on assay design, preanalytical performance characteristics, analytical performance characteristics, and clinical performance; and encourage regulatory agencies to adopt a minimal and uniform set of criteria for manufacturers to provide when seeking clearance for new and/or improved assays., Conclusions: These recommendations address the use of BNP and NT-proBNP as cardiac biomarkers and not their physiologic and/or pathophysiologic relevance.
- Published
- 2005
- Full Text
- View/download PDF
14. Multicenter evaluation of the TOSOH AIA-pack second-generation cardiac troponin I assay.
- Author
-
Pagani F, Stefini F, Micca G, Toppino M, Manoni F, Romano L, Hoffer P, Iervasi A, Caputo M, Dorizzi R, Zucchelli G, and Panteghini M
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Immunoassay instrumentation, Male, Middle Aged, Reference Values, Reproducibility of Results, Immunoassay methods, Myocardial Infarction diagnosis, Troponin I blood
- Published
- 2004
- Full Text
- View/download PDF
15. AACC creatine kinase MB (CK-MB) standardization material used as manufacturer's working calibrator is unable to harmonize CK-MB results between two commercial immunoassays.
- Author
-
Panteghini M and Pagani F
- Subjects
- Calibration, Creatine Kinase, MB Form, Humans, Immunoassay standards, Myocardial Infarction blood, Reference Standards, Creatine Kinase blood, Immunoassay methods, Isoenzymes blood, Myocardial Infarction enzymology
- Published
- 2004
- Full Text
- View/download PDF
16. Standardization of immunoassays for measurement of myoglobin in serum. Phase I: evaluation of candidate secondary reference materials.
- Author
-
Panteghini M, Linsinger T, Wu AH, Dati F, Apple FS, Christenson RH, Mair J, and Schimmel H
- Subjects
- Animals, Autoanalysis, Calibration, Cattle, Humans, Immunoassay instrumentation, Indicator Dilution Techniques, Indicators and Reagents, Myocardium chemistry, Reference Standards, Reproducibility of Results, Immunoassay standards, Myoglobin blood
- Abstract
Background: Myoglobin is a low-molecular weight protein present in the cytosol of striated muscles. Its concentrations in serum can be measured by immunoassays and are used as an early indicator of myocardial necrosis. Since variability among commercial myoglobin assays exists, standardization of myoglobin assays is needed., Methods: An international collaborative study was organized with the involvement of seven companies using 12 different automated platforms for measuring myoglobin. Five candidate secondary, i.e., matrixed, reference materials were assayed in relation to linearity, imprecision, recovery rate and commutability to demonstrate a possible identity between the materials and the usual routine serum samples., Results: One lyophilized candidate material (human heart myoglobin in human serum) was selected as the most suitable secondary reference material, based on the criteria examined. Used as a calibrator a posteriori, the bias between the various myoglobin assays for a frozen human serum pool was reduced from 32% to 13%., Conclusion: This study provides the basis for the selection of an internationally recognized secondary reference material.
- Published
- 2004
- Full Text
- View/download PDF
17. Current concepts in standardization of cardiac marker immunoassays.
- Author
-
Panteghini M
- Subjects
- Carcinoembryonic Antigen analysis, Humans, Myoglobin analysis, Reference Standards, Troponin I analysis, Biomarkers analysis, Immunoassay methods, Immunoassay standards, Myocardium metabolism
- Abstract
Cardiac markers are measured by a number of different immunoassays using specific antibodies directed to the respective antigens. Lacking assay standardization, different results from different assays measuring the same marker may be obtained and this problem may cloud interpretations of reported data. Presently, there are no reference procedures for cardiac markers; certified reference materials should still be established and, at least for cardiac troponins, the analyte in the patients' blood is significantly different from newly synthesized protein. It is therefore clear that the problems of cardiac marker standardization will not be quickly solved. A number of projects are, however, underway under the auspices of the IFCC and other organizations. The aim of this opinion is to reflect on some concepts related to the implementation of a metrologically correct measurement system, giving practical examples on how these concepts can be applied to immunoassays measuring cardiac markers.
- Published
- 2004
- Full Text
- View/download PDF
18. The measurement of cardiac markers: where should we focus?
- Author
-
Panteghini M
- Subjects
- Acute Disease, Humans, Immunoassay standards, Myocardium pathology, Myoglobin analysis, Reproducibility of Results, Troponin analysis, Biomarkers analysis, Immunoassay methods, Myocardial Infarction blood
- Abstract
Cardiac markers are presently a hot topic, with active debate on their use. They now have a major role for cost-effective management of acute chest pain and suspected acute coronary syndrome. The laboratory has a pivotal role in proper selection and interpretation of available markers, depending on the creation of evidence-based knowledge about test utilization and sources of variation. This article reviews this knowledge in the field of biomarkers determination and summarizes the major analytic and clinical issues, with reference to various recent recommendations of laboratory medicine and cardiology expert groups.
- Published
- 2002
- Full Text
- View/download PDF
19. Measurement Uncertainty of Thyroid Function Tests on a Chemiluminescent Microparticle Immunoassay System Needs to Be Improved.
- Author
-
Borrillo, Francesca, Pasqualetti, Sara, and Panteghini, Mauro
- Subjects
IMMUNOASSAY - Published
- 2023
- Full Text
- View/download PDF
20. A step forward in identifying the right human chorionic gonadotropin assay for testicular cancer.
- Author
-
Ferraro, Simona and Panteghini, Mauro
- Subjects
- *
CHORIONIC gonadotropins , *TESTICULAR cancer , *HUMAN rights , *TERATOCARCINOMA , *GONADOTROPIN , *LUTEINIZING hormone - Abstract
Clinical practice guidelines for the management of germ cell tumors recommend the measurements of human chorionic gonadotropin (hCG) and/or free hCGβ subunit for earlier diagnosis/recognition of the residual disease, for the prognostic evaluation and for the post-chemotherapy surveillance. However, the marketed hCG assays are validated and approved only for pregnancy purposes, with the sole exception of the Elecsys 'hCG+β' assay (Roche Diagnostics), cleared in Europe for oncological application. Theoretically, the hCG assay design for oncological purposes should fulfil the recommendations of the International Society of Oncology and Biomarkers requiring the use of antibodies displaying an equimolar recognition of both intact hCG and hCGβ monomer. Further analytical requirements should also be considered, such as optimal analytical sensitivity to allow an early tumor detection and low cross-reactivity for luteinizing hormone (LH). For the Elecsys assay, the detection limit (0.2 U/L) and the reported cross-reactivity for LH (0.12%) may be considered adequate if compared with the recommended requirements. Another issue is the definition of decision limits for oncologic purposes. After 3 years of clinical experience using the Elecsys assay in the oncology setting, we were able to define limits partitioned by sex and age as follows: males <50 years, 0.3 U/L; males >50 years, 2.3 U/L; female <50 years, 2.1 U/L; female >50 years, 5.6 U/L. There is an urgent need to disseminate appropriate educational information and to boost the clinical use of selective, highly sensitive and precise assays, specifically manufactured for cancer application. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Human chorionic gonadotropin in oncology: a matter of tight (bio)marking.
- Author
-
Ferraro, Simona, Incarbone, Giacomo Piero, Rossi, Roberta Simona, Dolci, Alberto, and Panteghini, Mauro
- Subjects
CHORIONIC gonadotropins ,ILIAC vein ,GONADOTROPIN ,ONCOLOGY ,TERATOCARCINOMA ,INSTITUTIONAL review boards - Abstract
The immunohistochemistry was negative for human chorionic gonadotropin (hCG) subunit, even in the areas with intratubular neoplasia. At admission, serum AFP was undetectable, total hCG (Elecsys "hCG+ " assay, Roche Diagnostics) was 30 U/L (recommended cut-off for men <50 years, 0.3 U/L) and lactate dehydrogenase (LDH) 898 U/L (upper reference limit [URL], 220 U/L). We observed that the behavior of LDH and hCG+ paralleled, and the hCG+ peak at 1.1 U/L was anticipated of 1 week by a sudden increase in LDH (547 U/L). At admission of the patient, clinicians erroneously ordered the hCG Abbott, so laboratory professionals corrected the request and then recommended the ordering of hCG+ Roche for further evaluation. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
22. SARS-CoV-2 serologic tests: do not forget the good laboratory practice.
- Author
-
Aloisio, Elena, Falvella, Felicia Stefania, Carnevale, Assunta, and Panteghini, Mauro
- Subjects
SERODIAGNOSIS ,SARS-CoV-2 - Abstract
3 Padoan, A, Cosma, C, Sciacovelli, L, Faggian, D, Plebani, M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Keywords: COVID-19; immunoassay; measurement uncertainty; quality control; SARS-CoV-2 EN COVID-19 immunoassay measurement uncertainty quality control SARS-CoV-2 e175 e177 3 04/12/21 20210501 NES 210501 To the Editor, Although the detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RNA in respiratory specimens remains the diagnostic standard for COVID-19, SARS-CoV-2 antibody testing has been advocated for identifying individuals who suffered infection. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
23. Making new biomarkers a reality: the case of serum human epididymis protein 4.
- Author
-
Ferraro, Simona and Panteghini, Mauro
- Subjects
- *
PROTEINS , *BIOMARKERS , *SERUM - Abstract
Background: Measurement of human epididymis protein 4 (HE4) in serum has recently been proposed for clinical use in the framework of ovarian cancer (OvCa). We sought to retrace the translational phase and the clinical implementation steps boosting HE4's clinical value and discuss the effects of its introduction on the diagnostic and management pathways. Methods: Meta-analyses of running evidence have preliminarily suggested that HE4 may overcome carbohydrate antigen 125 (CA125) in identifying OvCa, showing however several gaps that need to be considered, i.e. definition of biomarker diagnostic performance in the early detection of OvCa, added diagnostic value, biological and lifestyle factors of variation, and optimal interpretative criteria. Investigation of the influencing factors has shown that renal impairment represents a major limitation for HE4's diagnostic power. On the other hand, the demonstration of the substantial equivalence of results obtained by commercially available assays allows recommending harmonized thresholds for diagnostic purpose, even if the study of HE4's biological variation has clarified that the longitudinal interpretation of the biomarker changes according to the reference change value could be more appropriate. Summary: We used HE4 as an example for describing the long and bumpy road for making a new biomarker a reality, and the issues that should be checked and the information that should be provided in moving a novel biomarker from its discovery to an effective clinical adoption. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum.
- Author
-
Krintus, Magdalena, Braga, Federica, Kozinski, Marek, Borille, Simona, Kubica, Jacek, Sypniewska, Grazyna, and Panteghini, Mauro
- Subjects
CARDIOVASCULAR agents ,BIOLOGICAL tags ,IMMUNOASSAY ,SERUM ,REGRESSION analysis ,BIOLOGICAL variation - Abstract
Background: Growth differentiation factor 15 (GDF-15) is an emerging cardiovascular biomarker, and a fully automated immunoassay has recently become available. The objectives of the study were to identify biological and lifestyle factors affecting serum GDF-15 concentrations and derive robust reference intervals, and to estimate GDF-15 within-subject biological variation and derived indices. Methods: A presumably healthy population of 533 questionnaire-screened adults was used to identify the biological and lifestyle determinants of serum GDF-15. Following stringent exclusion criteria, a final group of 173 individuals was selected to establish GDF-15 reference interval. Twenty-six healthy volunteers were enrolled in the biological variation substudy. Results: Using a multiple regression model, age, B-type natriuretic peptide and C-reactive protein as well as smoking status were significantly related to serum GDF-15 concentrations. The upper reference limit (URL) for serum GDF-15 concentrations (90% confidence interval [CI]) was 866 ng/L (733–999 ng/L), with no sex-related difference. Although GDF-15 tended to increase with age, the weak dependence of marker from age does not justify age-related URL. The within-subject CV was 6.3% (95% CI, 4.5%–8.5%), with no sex difference in intraindividual variances. The reference change value (RCV) for GDF-15 was 23%, and two are the specimens required to ensure that the mean GDF-15 result is within ±10% of the individual's homeostatic set point. Conclusions: By identifying the main factors influencing serum GDF-15 concentrations, we robustly established the URL to be applied in adult population. As intraindividual variation of GDF-15 is relatively low, monitoring longitudinal changes in its concentrations over time using RCV can be a good alternative for interpreting GDF-15 in clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element.
- Author
-
Thelen, Marc, Vanstapel, Florent, Brguljan, Pika Meško, Gouget, Bernard, Boursier, Guilaine, Barrett, Edward, Kroupis, Christos, Lohmander, Maria, Šprongl, Luděk, Vodnik, Tatjana, Bernabeu-Andreu, Francisco, Vukasović, Ines, Sönmez, Çiğdem, Linko, Solveig, Brugnoni, Duilio, Vaubourdolle, Michel, Huisman, Willem, and Panteghini, Mauro
- Subjects
FOOD traceability ,CLINICAL pathology ,EPITOPES ,CALIBRATION ,IMMUNOASSAY - Abstract
ISO15189:2012 requires medical laboratories to document metrological traceability of their results. While the ISO17511:2003 standard on metrological traceability in laboratory medicine requires the use of the highest available level in the traceability chain, it recognizes that for many measurands there is no reference above the manufacturer's selected measurement procedure and the manufacturer's working calibrator. Some immunoassays, although they intend to measure the same quantity and may even refer to the same reference material, unfortunately produce different results because of differences in analytical selectivity as manufacturers select different epitopes and antibodies for the same analyte. In other cases, the cause is the use of reference materials, which are not commutable. The uncertainty associated with the result is another important aspect in metrological traceability implementation. As the measurement uncertainty on the clinical samples is influenced by the uncertainty of all steps higher in the traceability chain, laboratories should be provided with adequate and appropriate information on the uncertainty of the value assignment to the commercial calibrators that they use. Although the between-lot variation in value assignment will manifest itself as part of the long-term imprecision as estimated by the end-user, information on worst-case to be expected lot-lot variation has to be communicated to the end-user by the IVD provider. When laboratories use ancillary equipment that potentially could have a critical contribution to the reported results, such equipment needs verification of its proper calibration and criticality to the result uncertainty could be assessed by an approach based on risk analysis, which is a key element of ISO15189:2012 anyway. This paper discusses how the requirement for metrological traceability as stated in ISO15189 should be met by the medical laboratory and how this should be assessed by accreditation bodies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays and health outcomes.
- Author
-
Ferraro, Simona, Panzeri, Andrea, and Panteghini, Mauro
- Subjects
FOLIC acid deficiency ,IMMUNOASSAY ,DIAGNOSIS ,CLINICAL trials - Abstract
Several authors have recently claimed an excess in serum folate test ordering, suggesting phasing out it from clinical use. According to studies performed in countries undergoing folic acid fortification policies, it is indeed no more cost-effective to test folate in the face of deficiency prevalence < 1%. In this paper, we sought to evaluate request appropriateness, analytical issues, and cost-effectiveness of serum folate determination for clinical purposes in the European context, considering if evidence retrieved in fortified countries may be generalized. Studies performed in non-fortified countries have generally reported a suboptimal folate intake and suggest a remarkable prevalence of folate deficiency. Our internal data suggest that ~ 20%-25% of the subjects undergoing serum folate test are at risk for deficiency. However, a reliable evaluation of the risk for deficiency implies the knowledge of all issues related to the total testing process of folate measurement as well as the identification of the appropriate population in which to perform the test. The cost-effectiveness of the test is maximized when the request is oriented to subjects suggestive/at risk for deficiency, becoming low if the test is used as a screening tool or for monitoring of vitamin intake/supplementation. Because the individual folate status has a key role in ensuring normal development, physiologic growth, and maintenance of optimal health, the evaluation of its serum levels has to be retained in the clinical use in non-fortified countries, boosting for more appropriate request, and evidence from countries following fortification policies should be cautionary interpreted. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Laboratory medicine as the science that underpins medicine: the 'high-sensitivity' troponin paradigm.
- Author
-
Ferraro, Simona and Panteghini, Mauro
- Subjects
- *
CLINICAL pathology , *TROPONIN , *IMMUNOASSAY , *MYOCARDIAL revascularization ,MYOCARDIAL infarction diagnosis - Abstract
The availability of so-called high-sensitivity troponin assays (hsTn) has scored a compelling goal for laboratory medicine, allowing the safe clinical application of international recommendations for the definition of acute myocardial infarction (AMI). However, the introduction of hsTn has not been welcomed by clinicians, claiming an increase in false-positive results. Here we critically trace back the steps following the introduction of hsTn by referring to the 5-year practical experience in our academic hospital and to suitable information available in the literature. In agreement with published data, we found that hsTn introduction was associated with an increased number of AMI diagnoses, whereas the test volume, the revascularization rate, and the proportion of cases with negative angiography findings remained virtually unchanged. Fast-track protocols for ruling out AMI have been further optimized to recommend sampling at presentation and after 3 h only. We focus on a cost-effective use of hsTn that can account for all clinical variables increasing the pre-test probability in order to ensure that tests are ordered only for patients at medium to high risk for acute coronary syndrome (ACS). To guide interpretation of results, hsTn typical release patterns suggestive for AMI should be identified by evaluating the significance of concentration changes. hsTn have markedly shortened the time to rule out or rule in AMI and has the potential to improve the prognostic assessment of critical patients in clinical contexts different from ACS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Revaluating serum ferritin as a marker of body iron stores in the traceability era.
- Author
-
Ferraro, Simona, Mozzi, Roberta, and Panteghini, Mauro
- Subjects
SERUM ,FERRITIN ,IRON deficiency ,IMMUNOASSAY ,HEMOCHROMATOSIS - Abstract
Serum ferritin is used for diagnosing iron-related disorders. However, most studies validating this application were performed before the introduction of the 2nd and 3rd WHO International Standards (ISs) to harmonize assay results. We revised the available literature to evaluate if consolidated clinical applications of ferritin and recommended cut-offs have been validated using ISs calibrated assays. All Medline retrieved reviews and individual studies performed since ISs availability were selected and analyzed according to predefined criteria. Concerning ferritin and iron deficiency (ID), only one review, including studies published before 1988, met established criteria. Results showed that ferritin can effectively rule out ID anemia in patients with or without inflammatory disease at cut-offs of 70 and 40 μg/L, respectively. From two studies using ISs calibrated assays that met inclusion criteria, no information emerged on which cut-off should be employed to obtain similar sensitivity. Regarding iron overload, even when the framework was restricted to hereditary hemochromatosis, no synthesis of scientific evidence, if any, about diagnostic accuracy of ferritin was available both before and after ISs introduction. Available evidence of the ferritin diagnostic effectiveness is limited to ID conditions. Recommended cut-offs for this application are, however, based on studies published from 1970 to the 1980s using non-harmonized assays. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
29. Development of a candidate secondary reference procedure (immunoassay based measurement procedure of higher metrological order) for cardiac troponin I: I. Antibody characterization and preliminary validation.
- Author
-
Noble, James E., Bunk, David M., Christenson, Robert H., Cole, Kenneth D., He, Hua-Jun, Katrukha, Alexei G., Panteghini, Mauro, Porter, Robert A., Schimmel, Heinz, Tate, Jillian R., and Wang, Lili
- Subjects
IMMUNOASSAY ,HEART disease diagnostic equipment ,POLYACRYLAMIDE gel electrophoresis ,ANTIGEN-antibody reactions ,MONOCLONAL antibodies ,ENZYME-linked immunosorbent assay - Abstract
In this study, the first steps in the development of a secondary reference measurement procedure (RMP) 'higher metrological order measurement procedure' to support the cardiac troponin I (cTnI) standardization initiative is described. The RMP should be used to assign values to serum-based secondary reference materials (RMs) without analytical artifacts causing bias. A multiplexed bead-based assay and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) were used to identify the optimum monoclonal antibody pair (clones 560 and 19C7) for the RMP. Using these antibodies, an ELISA-based procedure was developed to accurately measure the main cTnI forms present in blood. The proposed RMP appears to show no bias when tested on samples containing various troponin complexes, phosphorylated and dephosphorylated forms, and heparin. The candidate assay displayed suitable linearity and sensitivity (limit of detection, 0.052 μg/L) for the measurement of the proposed cTnI secondary RMs. Preliminary comparison data on patient samples with a commercial cTnI assay are also provided to support the suitability of RMP for value assignment to RMs. Full validation and final assessment of the RMP will be performed through transferability and inter-comparison studies. Clin Chem Lab Med 2010;48:1603-10. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
30. A critical appraisal of experimental factors influencing the definition of the 99th percentile limit for cardiac troponins.
- Author
-
Panteghini, Mauro
- Subjects
- *
MYOCARDIAL infarction , *SERUM albumin , *BIOMARKERS , *IMMUNOASSAY - Abstract
The recently released document by the Global Task Force on the “universal” definition of myocardial infarction (MI) recommends a single decision limit for cardiac troponin (cTn) corresponding to the 99th percentile limit of the reference value distribution [99th upper reference limit (URL)] for the diagnosis of patients presenting with suspected MI. However, use of this cut-off concentration posed a problem because most assays do not have the sensitivity to consistently measure cTn in the blood of apparently healthy individuals, with a high proportion of the values being below the method's detection limit. In addition to the influence of assay sensitivity, the 99th URL for cTn can vary depending on the reference population used, and its sample size. A marked difference can also be observed between the 99th URL obtained using plasma vs. that obtained with serum. Finally, some interferences with cTn measurement (e.g., by heterophile antibodies) may become more noticeable using assays that have increased analytical sensitivity that measure lower concentrations of these markers. In conclusion, a number of issues can markedly influence the definition of the 99th URL for cTn, which most clinicians are unaware of and may markedly condition the clinical performance of the test in routine practice. Clin Chem Lab Med 2009;47:1179–82. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
31. Adult reference intervals for serum thyroid‐stimulating hormone using Abbott Alinity i measuring system.
- Author
-
Stefanska, Anna, Krintus, Magdalena, Siodmiak, Joanna, Wolska, Aleksandra, Szternel, Lukasz, Gackowska, Lidia, and Panteghini, Mauro
- Subjects
- *
LANGUAGE models , *THYROTROPIN , *LITERATURE reviews , *CARDIOVASCULAR diseases risk factors , *MANN Whitney U Test , *THYROID hormone regulation , *IMMUNOASSAY , *THYROTROPIN receptors , *THYROID gland function tests - Published
- 2024
- Full Text
- View/download PDF
32. Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction.
- Author
-
Ferraro, Simona, Bussetti, Marco, Bassani, Niccolò, Rossi, Roberta Simona, Incarbone, Giacomo Piero, Bianchi, Filippo, Maggioni, Marco, Runza, Letterio, Ceriotti, Ferruccio, and Panteghini, Mauro
- Subjects
CONFIDENCE intervals ,PREDICTIVE tests ,BIOPSY ,CALIBRATION ,IMMUNOASSAY ,CANCER patients ,DESCRIPTIVE statistics ,PROSTATE-specific antigen ,PREDICTION models ,LOGISTIC regression analysis ,ODDS ratio ,PROSTATE tumors ,PROBABILITY theory ,DISEASE risk factors - Abstract
Simple Summary: In this study, we used a well calibrated risk prediction model to define prostate-specific antigen (PSA) thresholds for identifying or excluding advanced prostate cancer (PCa) as an aid to personalize management of the diagnostic workup. PSA concentrations ≤ 4.1 (<65 years old) and ≤3.7 μg/L (≥65 years old) excluded an advanced PCa in patients without glandular inflammation, while PSA > 5.7 (<65) and >6.1 μg/L (≥65) suggested a biopsy referral. In the presence of glandular inflammation, PSA does not provide a valid estimate for risk of advanced cancer since the marker variability is higher and the pre-test probability of PCa is low in this group. The proposed PSA thresholds may allow an individualized approach to the diagnostic workup, assisting patients in making an informed decision. However, patients with asymptomatic prostatitis cannot benefit from the use of this model since they cannot be pre-biopsy identified. We defined prostate-specific antigen (PSA) thresholds from a well calibrated risk prediction model for identifying and excluding advanced prostate cancer (PCa). We retrieved 902 biopsied patients with a pre-biopsy PSA determination (Roche assay). A logistic regression model predictive for PCa including the main effects [i.e., PSA, age, histological evidence of glandular inflammation (GI)] was built after testing the accuracy by calibration plots and Hosmer-Lemeshow test for goodness of fit. PSA thresholds were derived by assuming a diagnostic sensitivity of 95% (rule-out) and 80% (rule-in) for overall and advanced/poorly differentiated PCa. In patients without GI, serum PSA concentrations ≤ 4.1 (<65 years old) and ≤3.7 μg/L (≥65 years old) excluded an advanced PCa (defined as Gleason score ≥ 7 at biopsy), with a negative predictive value of 95.1% [95% confidence interval (CI): 83.0–98.7] and 88.8% (CI: 80.2–93.9), respectively, while PSA > 5.7 (<65) and >6.1 μg/L (≥65) should address biopsy referral. In presence of GI, PSA did not provide a valid estimate for risk of advanced cancer because of its higher variability and the low pre-test probability of PCa. The proposed PSA thresholds may support biopsy decision except for patients with asymptomatic prostatitis who cannot be pre-biopsy identified. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Defining the plasma folate concentration for optimal neural tube defects prevention cannot ignore the impact of the employed methodology.
- Author
-
Ferraro, Simona and Panteghini, Mauro
- Subjects
NEURAL tube defect prevention ,ERYTHROCYTES ,AUTOMATION ,COST effectiveness ,FOLIC acid ,GLOBULINS ,IMMUNOASSAY - Published
- 2019
- Full Text
- View/download PDF
34. Estimation of the reference interval for serum folate measured with assays traceable to the WHO International Standard.
- Author
-
Ferraro, Simona, Panzeri, Andrea, Panteghini, Mauro, Borille, Simona, and Szoke, Dominika
- Subjects
FOLIC acid ,IMMUNOASSAY - Published
- 2017
- Full Text
- View/download PDF
35. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up.
- Author
-
Ferraro, Simona, Robbiano, Cristina, Tosca, Nicoletta, Panzeri, Andrea, Paganoni, Anna Maria, and Panteghini, Mauro
- Subjects
- *
OVARIAN cancer diagnosis , *BLOOD serum analysis , *EPIDIDYMIS , *BIOMARKERS , *DISEASE progression - Abstract
Abstract Background The addition of human epididymis protein 4 (HE4) to carbohydrate antigen 125 (CA125) in ovarian cancer (OC) assessment has been proposed. We compared the clinical value of biomarker changes in a prospective series of patients undergoing OC monitoring. Methods We studied 43 patients (79% post-menopausal), followed for 3.5 ± 3.1 years. Serous OC was prevalent (53.5%), with 81.4% of patients diagnosed at late stages. Both cut-offs and reference change values (RCV) were used for assessing significant marker changes. Results The use of cut-offs for CA125 and HE4 interpretation appeared equally fitting the evaluation of disease progression defined according to running guidelines, performing better than RCV criterion. However, both markers were simultaneously over cut-offs only in 46% of samples and changed in agreement in 35% of cases. The inspection of individual longitudinal trends indicated as main causes of disagreement the influence of renal impairment on HE4 concentrations and the more significant rate of decrease of CA125 vs. HE4 concentrations early after treatment. CA125 and HE4 changes according to RCV were not predictive of OC progression. Conclusions CA125 appears the most reliable biomarker for OC monitoring, whereas HE4 contributes additional information only in a minority of cases. Highlights • We compared CA125 and HE4 changes in ovarian cancer monitoring. • The use of cut-offs for CA125 and HE4 interpretation equally fitted the evaluation of disease progression. • CA125 and HE4 in the ovarian cancer follow-up may disagree for renal impairment/response to treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system
- Author
-
Braga, Federica, Dolci, Alberto, Montagnana, Martina, Pagani, Franca, Paleari, Renata, Guidi, Gian Cesare, Mosca, Andrea, and Panteghini, Mauro
- Subjects
- *
GLYCOSYLATED hemoglobin , *DIAGNOSIS of diabetes , *BLOOD testing , *IMMUNOASSAY , *SEX factors in disease , *ANALYSIS of variance , *DATA analysis - Abstract
Abstract: Background: Glycated hemoglobin (HbA1c) has a key role for diagnosing diabetes and monitoring glycemic state. As recently reviewed, available data on HbA1c biological variation show marked heterogeneity. Here we experimentally revaluated these data using a well designed protocol. Methods: We took five EDTA whole blood specimens from 18 apparently healthy subjects on the same day, every two weeks for two months. Samples were stored at −80°C until analysis and assayed in duplicate in a single run by Roche Tina-quant® Gen.2 immunoassay. Data were analyzed by the ANOVA. To assess the assay traceability to the IFCC reference method, we preliminarily carried out a correlation experiment. Results: The bias (mean±SD) of the Roche immunoassay was 0.3%±0.7%, confirming the traceability of the employed assay. No difference was found in HbA1c values between men and women. Within- and between-subject CV were 2.5% and 7.1%, respectively. Derived desirable analytical goals for imprecision, bias, and total error resulted 1.3%, 1.9%, and 3.9%, respectively. HbA1c had marked individuality, limiting the use of population-based reference limits for test interpretation. The estimated critical difference was ~10%. Conclusions: For the first time we defined biological variation and derived indices for the clinical application of HbA1c measurements using an accurately designed protocol and an assay standardized according to the IFCC. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
37. Multicenter evaluation of analytical performance of the Liaison® troponin I assay
- Author
-
Pagani, Franca, Stefini, Francesca, Chapelle, Jean-Paul, Lefèvre, Guillaume, Graïne, Hanafi, Luthe, Hilmar, Engelmayer, Jutta, and Panteghini, Mauro
- Subjects
- *
BLOOD plasma , *MYOCARDIAL infarction , *HEART diseases , *BLOOD circulation disorders - Abstract
Objectives: This study evaluated the analytical characteristics of the Liaison® immunoassay for cardiac troponin I (cTnI).Design and methods: The protocol consisted of eight sections: evaluation of antibody specificity, linearity, detection limit and imprecision, method comparison, evaluation of endogenous interferents, anticoagulant interference, sample stability, and reference values.Results: The assay equally measured free and complexed cTnI. The minimum detectable cTnI concentration was 0.021 μg/l. The cTnI concentration corresponding to a total CV of 10% was 0.056 μg/l. Linearity of response was demonstrated along the entire dynamic range of the assay. Assay interferences were minimal. cTnI concentrations in serum and heparinized plasma were significantly different. Values in EDTA plasma were on average approximately 5% higher than in matched serum, but this difference was not significant. The 99th percentile cTnI value in healthy subjects was 0.036 μg/l.Conclusions: Being sensitive, specific, and precise, the Liaison® cTnI assay meets current requirements to aid in the diagnosis of myocardial necrosis. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.